Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CytRx' purified RheothRxpf for sickle cell crisis awaiting FDA Phase III trial green light.

Executive Summary

CYTRx' "PURIFIED" RHEOTHRx TRIAL FOR SICKLE CELL CRISIS AWAITING FDA GO-AHEAD to begin Phase III clinical studies in the first quarter of 1997, company President and CEO Jack Luchese said during an Aug. 27 investor conference call. CytRx' RheothRxpf (polaxamer 188 N.F.) is a "purified version of the commercial grade" of the non-ionic copolymer surfactant rheologic compound used in earlier clinical trials conducted by CytRx and Glaxo Wellcome.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS028874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel